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The inhibition by imatinib of the cytochrome P450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of
clinically important coadministered drugs. The main purpose of this study was to evaluate the effect of the coadministration of
imatinib on the pharmacokinetics of simvastatin, a probe CYP3A4 substrate. In total, 20 patients with chronic myeloid leukaemia
received an oral dose of 40mg of simvastatin on study day 1. On study days 2–7, each patient received 400mg of imatinib once daily
orally and on study day 8, 400mg imatinib together with 40mg of simvastatin was given. Blood levels of simvastatin were measured
predose and for 24h postdose on study days 1 and 8. Two additional blood samples were taken for imatinib pharmacokinetic (PK)
assessment on day 8 before, and 24h after, imatinib administration. Imatinib increased the mean maximum concentration (Cmax)
value of simvastatin two-fold and the area under concentration–time curve (AUC (0–inf)) value 3.5-fold (Po0.001) compared with
simvastatin alone. There was a statistically significant decrease in total-body clearance of drug from the plasma (CL/F) with a mean
reduction of 70% for simvastatin (Po0.001): the mean half-life of simvastatin was prolonged from 1.4–2.7h when given together
with imatinib. No changes in imatinib PK parameters were found when given concomitantly with simvastatin. In conclusion, the
coadministration of imatinib at steady state with 40mg simvastatin increases the exposure (Cmax and AUCs) of simvastatin
significantly (Po0.001) by two-three-fold. Caution is therefore required when administering imatinib with CYP3A4 substrates with a
narrow therapeutic window. The coadministration of simvastatin with imatinib (400mg) was well tolerated and no major safety
findings were reported in this study.
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Imatinib mesylate (STI571, Glivec
s, Gleevec
s – Novartis, Basel,
Switzerland) is a potent competitive inhibitor of the tyrosine
kinases associated with ABL (Buchdunger et al, 1996; Druker et al,
1996), KIT (Buchdunger et al, 2000; Heinrich et al, 2000), PDGFr
(Buchdunger et al, 1996, 2000) and ARG (Okuda et al, 2001), which
impedes the interaction of ATP with the SH1 domain of these
proteins (Schindler et al, 2000), thereby inhibiting the phosphor-
ylation of downstream target proteins. Imatinib is a phenylami-
nopyrimidine derivative and represents the first of a new class of
drugs known as signal transduction inhibitors. Following initial
phase I/II dose-escalation studies with imatinib (Druker et al,
2001a,b), subsequent studies have demonstrated remarkable
efficacy with minimal side effects mostly in Philadelphia-positive
leukaemias (Kantarjian et al, 2002; Ottmann et al, 2002; Sawyers
et al, 2002; Talpaz et al, 2002; O’Brien et al, 2003) but also in solid
tumours (Joensuu et al, 2001). Currently, clinical trials using
imatinib with and without concomitant chemotherapy are being
conducted in a number of c-kit and PDGF-R-positive malignan-
cies(Apperley et al, 2001; Fischer et al, 2001; Johnson et al, 2002).
Imatinib is a competitive inhibitor of CYP3A4, CYP2D6
cytochrome P450 isoenzymes as well as CYP2C9, CYP3A5 and
CYP4A to a lesser extent (Novartis, unpublished data). Coadmi-
nistration of inhibitors of CYP3A4 with drugs known to be
substrates of this enzyme could potentially affect the pharmaco-
kinetic parameters of the substrate drug, and could be also
responsible for considerably increasing its side effects (Desager
and Horsmans, 1996). Simvastatin, an inhibitor of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, is used as a
lipid-lowering agent. It is uniquely metabolised by CYP3A4, is well
tolerated and is therefore commonly recommended as the model
drug for testing drug interactions involving CYP3A4 substrates
(US Department of Health and Human Services, 1999). Drug
interactions between CYP3A4 substrates such as simvastatin and
CYP3A4 inhibitors are potentially clinically important and have
been reported to potentially enhance the risk of myopathy and
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lrhabdomyolysis (Walker, 1989; Todd and Goa, 1990; Berland et al,
1991; Smith et al, 1991; Garnett, 1995; Meier et al, 1995; Goodman
& Gilman’s, The Pharmacological Basis of Therapeutics, 2000).
Accordingly, the prescription instructions for HMG-CoA reductase
inhibitors often suggest caution regarding the potential of
occurrence of drug interactions with substrates, inhibitors and
inducers of CYP3A compounds (Walker, 1989).
We therefore hypothesised that coadministration of imatinib, as
an inhibitor of the microsomal CYP3A4 enzyme system, could
affect the elimination rate of simvastatin. The present study was
undertaken to assess this potential pharmacokinetic interaction by
evaluation of the simvastatin plasma concentration vs time profiles
after coadministration with imatinib (US Department of Health
and Human Services, 1999) and its effects on safety and tolerability
in patients with chronic myeloid leukaemia (CML).
MATERIALS AND METHODS
Patient population
In an open-label, nonrandomised, one-sequence study, 20 adult
patients with CML who were haematologically or cytogenetically
resistant or refractory to interferon-a, or intolerant of interferon-a
were enrolled. There were 10 male and 10 female patients the mean
age (7s.d.) was 50.5 years (713.4 years), weight ranged from 53 to
111kg, and height from 158 to 192cm. None of the patients had
any past or present medical conditions that could affect the study
results. Each patient gave written informed consent before taking
part of the study, which was approved by the ethics committee of
the Landesa ¨rztekammer Rheinland-Pfalz, Mainz (Germany) and of
the University of Newcastle/Royal Victoria Infirmary (UK). The
study was conducted in agreement with the declaration of Helsinki,
as amended in Tokyo, Venice, Hong-Kong and Somerset West.
Drug interaction studies performed in healthy volunteers com-
monly use a crossover design. However, one of the requirements of
the present study was to test interactions with simvastatin at
steady-state levels of imatinib. As it usually requires approximately
7 days to reach serum steady-state levels of imatinib, it was
considered unethical to perform the study in healthy volunteers
and therefore the study was conducted in patients with CML. As a
corollary of this restriction, practical and ethical issues (e.g., wash-
out phase) prevented the study being performed as a crossover
design. The use of concomitant medications that could potentially
alter the integrity of the PK analysis (e.g., altered absorption,
distribution) was forbidden. The patients were asked to refrain
from strenuous physical exercise (e.g., weight training, aerobics,
football) for 7 days before dosing until after the study completion
evaluation, from alcohol for 72h before dosing until after the study
completion evaluation and from intake of xanthine (e.g., caffeine)
or grapefruit (known as a CYP3A4 inhibitor (Schmiedlin-Ren et al,
1997; Lilja et al, 1998; Kane and Lipsky, 2000))-containing food or
beverages 48h before dosing and during the whole study.
Study design
On study days 1 and 8, patients reported to the study site around
1h prior to dosing for baseline evaluations and were kept at the
centre until 12h postdosing (Table 1). At 24h after dosing, the
patients reported again to the study site for the 24h blood
sampling (study days 2 and 8) and study completion evaluations
(study day 9). Blood samples for determination of simvastatin
plasma concentrations were taken up to 24h after dosing on study
days 1 and 8. Imatinib was administered daily starting at day 2 at a
dose of 400mg (supplied as 100mg hard gelatine capsules).
Simvastatin (40mg tablets of Denan
s – Boehringer Ingelheim) for
both centres was purchased by the pharmacist of the University of
Mainz’s Hospital. On study days 1 and 8, 40mg of oral simvastatin
was administered immediately after a low fat breakfast (on day 8,
simvastatin and imatinib were given at the same time). No fluid
intake apart from the fluid given at the time of drug intake was
allowed until 2h after dosing. Owing to the inherent risk of either
reduced activity or enhanced toxicity of the concomitant medica-
tion and/or imatinib, drugs known to be metabolised by the same
CYP450 isoenzymes as imatinib, were forbidden. Allopurinol
300mg daily (an inhibitor of CYP2C9/10 (Yokochi et al, 1982;
Veronese et al, 1991; Kane and Lipsky, 2000)) was recommended
for patients with WBC 20.0 10
9l
 1. Following the PK study,
patients continued with therapeutic imatinib at the standard dose.
Blood sampling
All blood samples were taken by either direct venepuncture or an
indwelling cannula inserted in a forearm vein at predose (0h), 0.5,
1, 2, 3, 4, 6, 10, 12 and 24h after dosing on days 1 and 8 (Table 1).
Immediately after the blood was drawn, each tube was inverted
gently several times to ensure the mixing of tube contents (e.g.,
anticoagulant) and prolonged sample contact with the rubber
stopper was avoided. The upright tube was kept on ice, and within
30min the sample was centrifuged at 3 and 51C for 10min at
approximately 1500g. Immediately after centrifugation, at least
2ml plasma was transferred to a polypropylene screw-cap tube put
on dry ice. The tubes were kept frozen at p 181C pending
analysis.
Drug analysis
Simvastatin and simvastatin hydroxy acid with lovastatin as
internal standard were determined in plasma by LC/MS/MS. The
LC/MS/MS analyses were carried out on a Sciex API3000 mass
spectrometer. The instrument was operated in the ESI mode
(positive ion for drug, negative ion for metabolite) with selected
reaction monitoring. LC was performed on a Shimadzu LC system
operated in isocratic mode with a 2.0 50mm
2 C-18 column.
Samples were prepared using a solid-phase extraction procedure.
All concentrations are reported in terms of the free acid form of
simvastatin and simvastatin hydroxy acid.
Data analysis
All completed patients were included in the pharmacokinetic data
analysis. For plasma concentrations of simvastatin the following
parameters were determined: AUC(0–t) (area under the concentra-
tion–time curve from time zero to t), AUC(0–N) (area under the
concentration–time curve from time zero to infinity), Cmax
Table 1 Blood sampling schedule for pharmacokinetic analyses
Pretreatment period Pretreatment period Treatment period Treatment period Treatment period Post-treatment
Days  21 to  2:
screening evaluations
Period I: Period I: Period II: Period III: End of study evaluations 24h
after dosing day 8
Day  1: baseline
evaluations
Day 1: 40mg
simvastatin
Days 2–7: 400mg
Glivec od
Day 8: 400mg Glivec
od+40mg simvastatin
PK sampling PK sampling
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l(maximum plasma drug concentration), tmax (time to reach
maximum concentration following drug administration), t1/2
(elimination half-life associated with terminal slope of a semiloga-
rithmic concentration–time curve), Vz/f (apparent volume of
distribution based on terminal phase of plasma concentration–
time curves) and CL/F (total body clearance of drug from the
plasma), in order to assess the effects of imatinib on the PK of
simvastatin.
Statistical analysis
The following pharmacokinetic parameters were used to assess an
interaction of imatinib on simvastatin: AUCinf, AUCall, Cmax, Vz/f,
CL/f, t1/2 and tmax. With the exception of t1/2 and tmax, parameters
were ln-transformed prior to analysis. Treatment differences were
assessed by t-tests. The means of differences of ln-transformed
data together with 90% confidence intervals were then antilogged
in order to get confidence intervals for the ratio ‘simvasta-
tinþimatinib/simvastatin’. An interaction of imatinib with
simvastatin was assumed, if these confidence intervals were not
included in the ‘no-effect’ interval (0.80, 1.25). Tmax was analysed
nonparametrically. The alpha-level was set to 0.05 and no alpha-
adjustment was made for multiple testing.
RESULTS
Drug safety and tolerability
In total, 14 (70%) of the 20 recruited patients reported a total of 30
adverse events. All but one adverse events were rated by the
investigators as mild (grade 1) to moderate (grade 2). Of these, 12
patients had at least one adverse event grade 1, and four patients at
least grade 2. Only one patient experienced a grade 3 left leg
cellulitis, but this was assessed as not related to the study drugs.
No deaths occurred during the course of the study and none of the
adverse events resulted in discontinuation from the study. The
most common adverse events reported were neurological symp-
toms (headache, insomnia), gastrointestinal symptoms (nausea,
loose stool), and musculoskeletal symptoms (myalgia, muscle
cramps cramping, pain in limb).
Pharmacokinetics of simvastatin
The main pharmacokinetic parameters of simvastatin and its
hydroxy acid metabolite, for the 20 CML patients determined by
noncompartmental model analyses, are listed in Tables 2 and 3.
The mean and standard deviation for each parameter are given for
the two treatment periods in which simvastatin was administered.
Figures 1 and 2 show the mean plasma concentrations of
simvastatin and its metabolite (simvastatin hydroxy acid),
respectively, following either oral administration of simvastatin
alone or combined with oral administration of imatinib. Figure 3
Table 2 Simvastatin PK parameters following oral administration of
40mg simvastatin alone and combined with oral administration of 400mg
imatinib
Simvastatin plus imatinib Simvastatin alone
tmax (h)
a 1.0 (0.5–3.0) 1.0 (0.5–4.0)
Cmax (ngml
 1) 42.3725.8 23.3723.8
t1/2 2.771.3 1.470.8
AUC(0–all) (nghml
 1) 136.47113.6 45.5761.1
AUC(0–N) (nghml
 1) 137.77110.2 47.2760.4
Vz/F(l) 1543.07810.9 3115.972749.9
CL/F (lh
 1) 504.17431.8 2000.371975.3
aMedian (range). All unflagged values are mean7s.d. Mean and s.d. values are shown.
Table 3 PK parameters of simvastatin hydroxy acid following oral
administration of 40mg simvastatin alone and combined with oral
administration of 400mg imatinib
Simvastatin plus imatinib Simvastatin alone
tmax (h)
a 1.0 (0.5–3.0) 1.0 (0.5–4.0)
Cmax (ngml
 1) 24.9719.3 14.5713.3
t1/2 3.371.4 2.471.1
AUC(0–all) (nghml
 1) 116.17104.2 44.3741.7
AUC(0–N) (nghml
 1) 119.97106.0 51.9739.9
Mean and s.d. values are shown. See Table 2.
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Figure 1 Plasma concentrations (meanþs.d.) of simvastatin following
oral administration of simvastatin alone (J) and combined with
imatinib (&).
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Figure 2 Plasma concentrations (meanþs.d.) of simvastatin hydroxy
acid following oral administration of simvastatin alone (*) and combined
with imatinib (’).
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Figure 3 Comparison of AUC(0–N) of simvastatin following oral
administration of simvastatin alone and combined with Glivec
s (STI571).
Simvastatin alone shown in open columns, simvastatin plus imatinib shown
in black columns.
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lshows the comparison of plasma AUC(0–N) of simvastatin
following oral administration of simvastatin alone and combined
with oral administration of imatinib in 20 subjects. Following
imatinib coadministration, the mean simvastatin Cmax, AUC(0–all)
and AUC(0–N) increased significantly by two-to-three-fold
(Po0.001). There was a statistically significant decrease in CL/F
with a mean reduction of 70% (Po0.001). With regard to
metabolites, the mean Cmax and AUCs of simvastatin hydroxy
acid also increased significantly by two-to-three-fold (Po0.001)
after imatinib treatment (Table 3 and Figure 2). The coefficient of
variation (CV) for Cmax and AUCs showed considerable inter-
patient variation. The mechanism for this variability is not clear
yet but could be attributed to interpatient variations in CYP3A4
activity. Compliance to imatinib treatment and plasma concentra-
tion at steady state were checked by the analysis of the plasma
samples taken on study days 8 and 9 in the morning prior to
administration. The mean plasma imatinib trough concentrations
were similar on day 8 (1268ngml
 1) and day 9 (1182ngml
 1)
indicating that PK steady state for imatinib was reached in those
patients after 6-day oral doses.
DISCUSSION
This study was performed to determine whether imatinib could
alter the pharmacokinetics of a single dose of simvastatin when
given concomitantly in patients with chronic myeloid leukaemia.
This has important implications because of potential interactions
of imatinib with commonly prescribed drugs in the clinic.
The major route of degradation of simvastatin within the body is
by cytochrome P450 3A4-mediated biotransformation (Vickers
et al, 1990; Prueksaritanont et al, 1997) although the drug can be
converted reversibly to simvastatin hydroxy acid by esterases.
From in vitro drug interaction studies, CYP3A4 was also found to
be the major human P450 enzyme involved in the microsomal
biotransformation of imatinib (data not shown). Simvastatin
inhibits HMG-CoA reductase causing decreases in intrahepatic
cholesterol and upregulation of LDL-receptors with enhanced
clearance of LDL and other apolipoprotein B containing lipopro-
teins from the circulation. It appears that these interactions do not
have a relevant clinical effect on the efficacy of the HMG-CoA
reductase inhibitors to reduce the cLDL from the plasma, but the
concomitant administration of HMG-CoA reductase inhibitors and
cyclosporine, fibrate or nicotinic acid may enhance the risk of
myopathy or rhabdomyolysis (Berland et al, 1991; Smith et al,
1991; Meier et al, 1995).
The coadministration of simvastatin with imatinib (400mg) was
well-tolerated and no major safety concerns were reported in this
study. No clinically significant abnormalities in laboratory values,
vital signs or ECGs were reported. The majority of the adverse
events were assessed as grade 1/2 and no myopathy or
rhabdomyolysis occurred. Only one grade 3 left leg cellulitis
(which required hospitalisation) was reported but was not related
to the study drugs. This study shows that coadministration of
imatinib increased the mean Cmax value of simvastatin two-fold
and the AUC(0–N) value three-fold compared with simvastatin
alone and the mean half-life of simvastatin was prolonged from 1.4
to 2.7h when given together with imatinib. This indicates an
inhibition of CYP3A4 by which the oxidative biotransformation of
simvastatin to other metabolites is primarily mediated. It was also
observed that the formation of simvastatin hydroxy acid from
simvastatin by esterases is not prevented by imatinib, which
explains the increases in both simvastatin and simvastatin hydroxy
acid concentrations. This would suggest that in the presence of
imatinib, plasma levels of standard doses of drugs which are
degraded by the CYP3A4 system (Table 4 and see also: http://
medicine.iupui.edu/flockhart/) may be increased. For example, one
might predict that the effects of warfarin, digoxin, certain
antihypertensive agents (e.g., diltiazem, nifedipine, verapamil),
steroids, benzodiazepines and other drugs commonly used in the
practice of haematology (e.g., busulphan, cyclosporine, cyclopho-
sphamide, doxorubicin etoposide, vincristine) could be enhanced
and appropriate vigilance to avoid undesirable effects should be
exercised. In addition, concomitant use of simvastatin or other
HMG-CoA reductase inhibitors with imatinib may increase the
risk of myopathy or rhabdomyolysis and again caution is required.
The design of the study allows only limited interpretation of the
effects of simvastatin on plasma levels, and perhaps therefore
efficacy, of imatinib. However there were no apparent effects of
simvastatin on the PK of imatinib in these 20 patients, although
more detailed PK studies would be required to resolve this issue
definitively. Although this study was not designed to assess the
potential relationships between the efficacy of imatinib and
pharmacokinetics parameters, this important question is being
addressed by ongoing population PK/PD modelling analyses
within the context of ongoing phase II and phase III studies.
In conclusion, the coadministration of imatinib (400mg)
at steady state with 40mg simvastatin significantly (Po0.001)
Table 4 Substrates of cytochrome P450 enzymes CYP3A3/4
Substrates: imatinib may increase the potency of these drugs
Acetaminophen, Alfentanil, Alosetron, Alprazolam, Amiodarone, Amitriptyline (minor), Amlodipine, Anastrozole, Androsterone, Antipyrine, Astemizole, Atorvastatin,
Benzphetamine, Bepridil, Bexarotene, Bromazepam, Bromocriptine, Budesonide, Bupropion (minor), Buspirone, Busulphan, Caffeine, Cannabinoids, Carbamazepine,
Cerivastatin, Cevimeline, Chlorpromazine, Cimetidine, Cisapride, Citalopram, Clarithromycin, Clindamycin, Clomipramine, Clonazepam, Clozapine, Cocaine, Codeine
(demethylation), Cortisol, Cortisone, Cyclobenzaprine (demethylation), Cyclophosphamide, Cyclosporine, Dapsone, Dehydroepiandrostendione, Delavirdine,
Desmethyldiazepam, Dexamethasone, Dextromethorphan (minor, N-demethylation), Diazepam (minor;hydroxylation, N-demethylation), Digitoxin, Diltiazem,
Disopyramide, Docetaxel, Dofetilide (minor), Dolasetron, Donepezil, Doxorubicin, Doxycycline, Dronabinol, Enalapril, Erythromycin, Estradiol, Ethinyl Estradiol,
Ethosuximide, Etoposide, Exemestene, Felodipine, Fentanyl, Fexotenadine, Finasteride, Fluoxetine, Flutamide, Glyburide, Granisetron, Halofantrine, Hydrocortisone,
Hydroxyarginine, Ifosfamide, Imipramine, Indinavir, Isradipine, Itraconazole, Ketoconazole, Lansoprazole (minor), Letrozole, Levobupivicaine, Lidocaine, Loratadine, Losartan,
Lovastatin, Methadone, Mibefradil, Miconazole, Midazolam, Mifepristone, Mirtazapine (N-demethylation), Montelukast, Navelbine, Nefazodone, Nelfinavir, Nevirapine,
Nicardipine, Nifedipine, Niludipine, Nimodipine, Nisoldipine, Nitrendipine, Omeprazole (sulfonation), Ondansetron, Oral contraceptives, Orphenadrine, Paclitaxel,
Pantoprazole, Pimozide, Pioglitazone, Pravastatin, Prednisone, Progesterone, Proguanil, Propafenone, Quercetin, Quetiapine, Quinidine, Quinine, Repaglinide, Retinoic acid,
Rifampin, Risperidone, Ritonavir, Salmeterol, Saquinavir, Sertindole, Sertraline, Sibutramine, Sildenalfil citrate, Simvastatin, Sirolimus, Sufentanil, Tacrolimus, Tamoxifen,
Temazepam, Teniposide, Terfenadine, Testosterone, Tetrahydrocannabinol, Theophylline, Tiagabine, Tolterodine, Toremifene, Trazodone, Tretinoin, Triazolam,
Troglitazone, Troleandomycin, Venlafaxine (N-demethylation), Verapamil, Vinblastine, Vincristine, Warfarin (R-warfarin), Yohimbine, Zaleplon (minor pathway),
Zatoestron, Zileuton, Ziprasidone, Zolpidem, Zonisamide.
Simvastatin in bold is a substrate for CYP3A4 and in this study, coadministration with imatinib resulted in significantly increased mean maximum concentration and area under
concentration–time curve values for simvastatin. One might expect coadministration with imatinib to increase the potency of these drugs. Caution is also required with drugs
which induce or inhibit CPY3A4. Adapted from Cytochrome P-450 Enzymes and Drug metabolism. (In: Lacy CF, Armstrong LL, Goldman MP, Lance LL (eds) Drug Information
Handbook, 8th edn. Hudson, OH: LexiComp Inc. 2000: pp 1364–1371).
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lincreases the exposure (Cmax and AUCs) to simvastatin by
two-to-three-fold. This effect is most likely the result of
the inhibition of CYP3A4-mediated metabolism of simvastatin
in the liver and has implications for the monitoring of con-
comitant therapies in patients being treated with imatinib.
Caution is therefore required when administering
imatinib with CYP3A4 substrates with a narrow therapeutic
window.
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